Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment.

Chow EK, Zhang XQ, Chen M, Lam R, Robinson E, Huang H, Schaffer D, Osawa E, Goga A, Ho D.

Sci Transl Med. 2011 Mar 9;3(73):73ra21. doi: 10.1126/scitranslmed.3001713.

PMID:
21389265
[PubMed - indexed for MEDLINE]
Free Article
2.

Dodging drug-resistant cancer with diamonds.

Merkel TJ, DeSimone JM.

Sci Transl Med. 2011 Mar 9;3(73):73ps8. doi: 10.1126/scitranslmed.3002137.

PMID:
21389261
[PubMed - indexed for MEDLINE]
3.

Active nanodiamond hydrogels for chemotherapeutic delivery.

Huang H, Pierstorff E, Osawa E, Ho D.

Nano Lett. 2007 Nov;7(11):3305-14. Epub 2007 Oct 5.

PMID:
17918903
[PubMed - indexed for MEDLINE]
4.

In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.

Wong HL, Rauth AM, Bendayan R, Wu XY.

Eur J Pharm Biopharm. 2007 Mar;65(3):300-8. Epub 2006 Nov 7.

PMID:
17156986
[PubMed - indexed for MEDLINE]
5.

Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.

Liang G, Tang A, Lin X, Li L, Zhang S, Huang Z, Tang H, Li QQ.

Int J Oncol. 2010 Jul;37(1):111-23.

PMID:
20514403
[PubMed - indexed for MEDLINE]
6.

Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs.

Liu SQ, Wiradharma N, Gao SJ, Tong YW, Yang YY.

Biomaterials. 2007 Mar;28(7):1423-33. Epub 2006 Dec 1.

PMID:
17141308
[PubMed - indexed for MEDLINE]
7.

Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.

Prakash J, Beljaars L, Harapanahalli AK, Zeinstra-Smith M, de Jager-Krikken A, Hessing M, Steen H, Poelstra K.

Int J Cancer. 2010 Apr 15;126(8):1966-81. doi: 10.1002/ijc.24914.

PMID:
19795464
[PubMed - indexed for MEDLINE]
8.

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.

Clin Cancer Res. 2002 Apr;8(4):1172-81.

PMID:
11948130
[PubMed - indexed for MEDLINE]
Free Article
9.

Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.

Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X, Mao Y, Wei Y, Chen L.

J Control Release. 2010 Jul 1;145(1):17-25. doi: 10.1016/j.jconrel.2010.03.007. Epub 2010 Mar 20.

PMID:
20307599
[PubMed - indexed for MEDLINE]
10.

Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo.

Al-Jamal KT, Al-Jamal WT, Wang JT, Rubio N, Buddle J, Gathercole D, Zloh M, Kostarelos K.

ACS Nano. 2013 Mar 26;7(3):1905-17. doi: 10.1021/nn305860k. Epub 2013 Mar 7.

PMID:
23527750
[PubMed - indexed for MEDLINE]
12.

Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.

Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q.

Eur J Pharm Biopharm. 2010 Mar;74(3):467-73. doi: 10.1016/j.ejpb.2010.01.002. Epub 2010 Jan 11.

PMID:
20064608
[PubMed - indexed for MEDLINE]
13.

Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.

Szepeshazi K, Schally AV, Nagy A.

Breast Cancer Res Treat. 1999 Aug;56(3):267-76.

PMID:
10573117
[PubMed - indexed for MEDLINE]
14.

Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.

Jiang J, Yang SJ, Wang JC, Yang LJ, Xu ZZ, Yang T, Liu XY, Zhang Q.

Eur J Pharm Biopharm. 2010 Oct;76(2):170-8. doi: 10.1016/j.ejpb.2010.06.011. Epub 2010 Jun 25.

PMID:
20600887
[PubMed - indexed for MEDLINE]
15.

Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells.

Chu AC, Tsang SY, Lo EH, Fung KP.

Life Sci. 2001 Dec 21;70(5):591-601.

PMID:
11811903
[PubMed - indexed for MEDLINE]
16.

Galactosylated α,β-poly[(2-hydroxyethyl)-L-aspartamide]-bound doxorubicin: improved antitumor activity against hepatocellular carcinoma with reduced hepatotoxicity.

Cheng X, Gao F, Xiang J, Jiang X, Chen J, Zhang J.

Anticancer Drugs. 2011 Feb;22(2):136-47. doi: 10.1097/CAD.0b013e3283406e85.

PMID:
20966743
[PubMed - indexed for MEDLINE]
17.

Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure.

Frenkel V, Etherington A, Greene M, Quijano J, Xie J, Hunter F, Dromi S, Li KC.

Acad Radiol. 2006 Apr;13(4):469-79.

PMID:
16554227
[PubMed - indexed for MEDLINE]
18.

targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.

Du B, Han H, Wang Z, Kuang L, Wang L, Yu L, Wu M, Zhou Z, Qian M.

Mol Cancer Res. 2010 Feb;8(2):135-44. doi: 10.1158/1541-7786.MCR-09-0339. Epub 2010 Feb 9.

PMID:
20145035
[PubMed - indexed for MEDLINE]
Free Article
19.

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.

J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.

PMID:
18695136
[PubMed - indexed for MEDLINE]
Free Article
20.

Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.

Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F.

J Drug Target. 2003 Apr;11(3):139-49.

PMID:
13129824
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk